PMID- 10874886
OWN - NLM
STAT- MEDLINE
DCOM- 20000713
LR  - 20141120
IS  - 0002-9173 (Print)
IS  - 0002-9173 (Linking)
VI  - 113
IP  - 6
DP  - 2000 Jun
TI  - HER-2/neu gene amplification compared with HER-2/neu protein overexpression and 
      interobserver reproducibility in invasive breast carcinoma.
PG  - 852-9
AB  - We compared the detection of HER-2/neu gene amplification by fluorescence in situ 
      hybridization (FISH) with detection of HER-2/neu protein overexpression by 
      immunohistochemistry using 2 antibodies on 100 archival invasive breast 
      carcinomas. Protein overexpression for each marker was scored independently by 4 
      pathologists using standardized criteria, and consensus was compared with results 
      obtained from gene amplification. The concordance rate between FISH and 
      immunohistochemistry was 76% for e2-4001 and 91% for the HercepTest. Of the 37 
      cases positive by e2-4001, 21 demonstrated no gene amplification; 7 of 24 cases 
      positive by the HercepTest demonstrated no gene amplification. However, 1 of 61 
      cases negative by e2-4001 showed gene amplification; none of the cases negative 
      by the HercepTest showed amplification. The predictive values of gene 
      amplification based on 0-1+, 2+, and 3+ immunohistochemical staining were best 
      for cases scored as 3+ (75% for e2-4001 and 89% for the HercepTest). Complete 
      agreement among observers for immunohistochemical scoring of e2-4001 and the 
      HercepTest was achieved in 75 and 85 cases, respectively. The pairwise kappa 
      agreement values were substantial for e2-4001 and substantial to almost perfect 
      for the HercepTest. Immunohistochemical staining may be considered a useful 
      screening test. While negative staining almost always correlated with a lack of 
      gene amplification, positive membranous staining, especially 2+, did not predict 
      gene amplification. The low interobserver reproducibility in separating 2+ from 
      3+ cases necessitates further confirmation by FISH before treatment decisions are 
      made.
FAU - Hoang, M P
AU  - Hoang MP
AD  - Department of Pathology, University of Texas M.D. Anderson Cancer Center, Houston 
      77030, USA.
FAU - Sahin, A A
AU  - Sahin AA
FAU - Ordonez, N G
AU  - Ordonez NG
FAU - Sneige, N
AU  - Sneige N
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Am J Clin Pathol
JT  - American journal of clinical pathology
JID - 0370470
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adenocarcinoma/*genetics/metabolism/pathology
MH  - Adult
MH  - Aged
MH  - Breast Neoplasms/*genetics/metabolism/pathology
MH  - Evaluation Studies as Topic
MH  - Female
MH  - *Gene Amplification
MH  - Genes, erbB-2/*genetics
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - In Situ Hybridization, Fluorescence
MH  - Middle Aged
MH  - Observer Variation
MH  - Predictive Value of Tests
MH  - Receptor, ErbB-2/*biosynthesis
MH  - Reproducibility of Results
EDAT- 2000/06/30 11:00
MHDA- 2000/07/15 11:00
CRDT- 2000/06/30 11:00
PHST- 2000/06/30 11:00 [pubmed]
PHST- 2000/07/15 11:00 [medline]
PHST- 2000/06/30 11:00 [entrez]
AID - 10.1309/VACP-VLQA-G9DX-VUDF [doi]
PST - ppublish
SO  - Am J Clin Pathol. 2000 Jun;113(6):852-9. doi: 10.1309/VACP-VLQA-G9DX-VUDF.